However, the lesion criteria for the use of ESD, rather than strip biopsy, remain to be elucidated. Methods: On the basis of reviews of literature and our observations concerning the outcome of strip biopsy, we set the criteria for selecting strip biopsy and ESD as follows. The indications for strip biopsy were lesions less than 10 mm in size and located in the anterior wall or greater curvature of the lower and middle stomach. ESD was indicated for all other lesions. The validity of the criteria was then analyzed prospectively in 156 patients. The rate of en bloc R0 resection and local recurrence were evaluated.
Results: Subsequently, 156 lesions were divided according to the criteria and were endoscopically Smoothened Agonist resected by strip biopsy (n = 13) or ESD (n = 143). The en bloc R0 resection rates for the whole group and KU-57788 mw the strip biopsy and ESD groups was 93.5% (146/156), 92.3% (12/13), and 93.7% (134/143), respectively. None of the patients had suffered from local recurrence in either the strip biopsy or ESD groups. Conclusion: The validity of our criteria for selecting strip biopsy and ESD was verified. Our criteria exploit the advantages of both procedures and obtain better endoscopic therapy outcomes for EGC. “
“Adult patients with cystic fibrosis (CF) have an increased risk of gastrointestinal malignancies.
We hypothesized that increased intestinal cell turnover beginning in childhood may explain the increased risk of malignancy in early adulthood.
Therefore we aimed to measure faecal M2-pyruvate kinase (M2-PK), a biomarker of intestinal cell turnover, in children with CF. To assess whether the increased cell turnover is secondary to intestinal inflammation, the secondary aims were to measure faecal calprotectin and evaluate its association with faecal M2-PK. Faecal samples, for Dapagliflozin M2-PK and calprotectin measurements, were prospectively collected from children with CF and healthy controls (HC). Thirty-three children with CF (mean (SD) 7.3 (3.8) years old; 29 pancreatic insufficient (PI)) were enrolled and compared to 33 age-matched HC. Faecal M2-PK in CF patients (median (interquartile range (IQR)): 4.7 (1.5 – 9.7)) was greater than HC (1.0 (1.0 – 1.0) U/ml; P < 0.0001), and higher in PI (median (IQR): 5.1 (1.8 – 13.7)) than pancreatic sufficient patients (1.0 (1.0 – 1.0) U/ml; P = 0.002). Faecal calprotectin was significantly elevated in CF than HC (median (IQR) 61.3 (43.8 – 143.8) vs. 19.5 (19.5 – 35.1) mg/kg; P < 0.0001). However, there was no correlation between faecal M2-PK and faecal calprotectin levels among subjects with CF (r = 0.29; P = 0.1). Increased intestinal cell turnover is present in children with PI CF. The lack of relationship between faecal M2-PK and calprotectin suggests contributing factor(s) other than inflammation may be present.